anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Doxorubicin is an effective antineoplastic agent but has limited clinical application because of its cumulative toxicities, including cardiotoxicity. Cardiotoxicity causes lipid peroxidation, genetic impairment, oxidative stress, inhibition of autophagy, and disruption of calcium homeostasis. Doxorubicin-induced cardiotoxicity is frequently tried to be mitigated by phytochemicals, which are derived from plants and possess antioxidant, anti-inflammatory, and anti-apoptotic properties. Arbutin, a natural antioxidant found in the leaves of the bearberry plant, has numerous pharmacological benefits, including antioxidant, anti-bacterial, anti-hyperglycemic, anti-inflammatory, and anti-tumor activity.
METHODS AND RESULTS: The study involved male Wistar rats divided into three groups: a control group, a group treated with doxorubicin (20 mg/kg) to induce cardiac toxicity, a group treated with arbutin (100 mg/kg) daily for two weeks before doxorubicin administration. After treatment, plasma and heart tissue samples were collected for analysis. The samples were evaluated for oxidative stress parameters, including superoxide dismutase, malondialdehyde, and catalase, as well as for cardiac biomarkers, including CK, CK-MB, and LDH. The heart tissues were also analyzed using molecular (TNF-α, IL-1β and Caspase 3), histopathological and immunohistochemical methods (8-OHDG, 4 Hydroxynonenal, and dityrosine). The results showed that arbutin treatment was protective against doxorubicin-induced oxidative damage by increasing SOD and CAT activity and decreasing MDA level. Arbutin treatment was similarly able to reverse the inflammatory response caused by doxorubicin by reducing TNF-α and IL-1β levels and also reverse the apoptosis by decreasing caspase-3 levels. It was able to prevent doxorubicin-induced cardiac damage by reducing cardiac biomarkers CK, CK-MB and LDH levels. In addition to all these results, histopathological analyzes also show that arbutin may be beneficial against the damage caused by doxorubicin on heart tissue.
CONCLUSION: The study suggests that arbutin has the potential to be used to mitigate doxorubicin-induced cardiotoxicity in cancer patients.
Use this medication only as directed by the healthcare provider. It is for external use only. Avoid contact with the eyes. If Mupirocin Ointment USP, 2% gets in or near the eyes, rinse thoroughly with water. The medication should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs. If impetigo has not improved in 3 to 5 days, contact the healthcare provider.

### \- Drug Interactions

The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied.
Theory allows researchers to systematically explain and predict health behavior by providing an organized framework to approach research questions; the importance of theory is particularly emphasized in meta-analyses demonstrating that interventions designed from the basis of health behavior theory are more successful than those that are not theory-based. The superiority of theory-based interventions has been established, but these meta-analyses do not answer the important questions of which theoretical constructs may be the "active ingredients" of change nor of how constructs in a particular theory may work separately versus in combination to produce the greatest amount of behavior change. Health interventions on the whole have only small to moderate effects on behavior change, and perhaps this is partly due to a lack of solid understanding of how key theoretical constructs influence each other to motivate behavior change. Often times when a theory is used as the basis for an intervention only a subset of the constructs seem to produce behavior change, which calls into question the sufficiency of our current theories for producing behavior change. One possible reason for this may be that current health behavior theories are really theories of behavioral prediction and not behavior change.

Health behavior theories are often used to inform intervention development-assuming that the same cognitive processes that successfully explain behavior are also the same processes that can be targeted to elicit behavior change. Past reviews show that theories like the Theory of Planned Behavior (TPB) explain 30%-50% of the variance in behavior, and when behavior change is the outcome the same predictors only produce small to moderate effects. However, it is unclear if the same predictors are working together in a similar way when using them to explain behavior versus creating behavior change. Currently, the same cognitive mechanisms are used to describe both processes, but those that explain behavior may not be the same ones that produce behavior change. There is very little literature that addresses how these processes may differ. A careful examination of the extent to which current theoretical constructs successfully produce behavior change individually or in combination may help clarify the optimal theoretical framework that should be utilized in behavior change interventions. Using the Theory of Planned Behavior (TPB) as the guiding theoretical framework, this study explores one way to experimentally determine how the constructs in the TPB influence each other and successfully produce health behavior change.
This study investigated the impact of prior antidepressant and stimulant exposure on the age at onset (AAO) of first episode mania (FEM) or psychosis (FEP). Patients with FEP and FEM born after 1985 in Olmsted County, Minnesota, were identified using the Rochester Epidemiology Project. Duration and peak dose of antidepressant and stimulant exposure were quantified by review of the electronic health record. Peak doses were converted to defined daily dose (DDD), and cumulative exposure was calculated as DDD multiplied by treatment duration. Linear models were used to assess relationships between AAO with any exposures, and cumulative antidepressant and stimulant exposures. A total of 190 FEM/FEP patients (mean AAO=20.8 ± 3.7 years) were included. There was no significant difference in AAO with vs. without exposure to antidepressants or stimulants. Cumulative antidepressant exposure correlated with a later AAO in overall sample (r = 0.28, p < 0.001), and in FEP (r = 0.33, p < 0.001). No significant correlation emerged between cumulative stimulant exposure and AAO. Multivariable modeling confirmed that cumulative antidepressant exposure (Estimate=2.42, 95 %CI=1.66-3.18, p < 0.001), but not cumulative stimulant exposure (Estimate=-0.04, 95 %CI=-1.10-1.02, p = 0.94), was associated with later AAO. Antidepressant and stimulant exposures were not associated with earlier AAO. However, cumulative antidepressant exposure was associated with later AAO. Limitations include retrospective design and relatively small sample size. Our findings may inform adolescent treatment recommendations when assessing risk for psychotropic-related adverse events. Further risk modeling investigations of antidepressants and stimulants with larger sample sizes are needed to explore the role of antidepressant and stimulant exposure in the trajectory leading to FEM/FEP.
Full thickness flap elevated, then elevation of sinus floor by Osteotome, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device then flap sutured. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
The entire study is divided into two stages. Stage one is the enrollment period. 51 subjects with pancreatic ductal adenocarcinoma in stages I-II who have not received neoadjuvant therapy and have undergone radical surgery were enrolled. Blood samples at the time point before surgical treatment (T0) were collected and fresh tissue specimens (cancerous tissue and adjacent normal tissue) were collected. Blood samples were subjected to methylation, fragment group, and CNV multi-omics testing, and tissue samples were subjected to target methylation area testing. Stage two is the follow-up period. Blood samples from the fifth week after surgery to before adjuvant therapy (T1) and blood samples from 4-8 weeks after adjuvant therapy (T2) were collected. Blood samples were subjected to methylation, fragment group, and CNV multi-omics testing with different techniques. The subjects were followed up for 1.5 years. According to progression and recurrence, the subjects were divided into progression group and non-progression group. Methylation and multi-omics prognosis models were trained and compared for their performance in residual detection and recurrence prediction.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of orthopedic dentistry. Removable denture includes elastic pad and rigid basis with artificial teeth. Rigid basis is made from polyurethane composition based on di-isocyanate and polyatomic alcohol, where as di-isocyanate used is pseudoforpolymer, containing NCO-groups in amount 16.5-17.0%, and as polyatomic alcohol, used is polyoxypropylene and/or oligooxypropylene-polyatomic alcohols with definite molecular weight. Elastic pad of denture is made from polyurethane composition based on poly-isocyanate with content of NCO-groups from 2.2 to 33.1%, oligopolyatomic alcohol, such as oligooxypropylene glycol or olygooxypropylenetriol with moleculare weight from 500 to 5000, and catasyst - dibutyldilaurate of octoate of tin. Polyurethane compositions can contain additional components such as dyes, light-stabiliser, ethylene glycol, etc. Polyuretghane compositions, of which removable denture is made, and method of denture manufacturing ensure increase of removable denture basis hardness, increase of strength characteristics of denture material with simultaneous increase of service life of manufactured removable denture, as well as improvement of technological characteristics in process of denture manufacturing. ^ EFFECT: there is claimed removable denture and method of its manufacturing. ^ 9 cl, 3 tbl, 2 ex
Alteration of choroidal blood supply causes changes in choroidal thickness and results in choroidal abnormalities. These are usually associated with retinal diseases and leading to severe visual dysfunction. Choroidal thickness is therefore helpful in diagnosis and treatment for many chorioretinal conditions. With the advent of spectral domain optical coherence tomography and enhanced depth imaging technique, choroidal thickness has been investigated widely in normal eyes and various chorioretinal diseases including central serous chorioretinopathy (CSC), age-related macular degeneration (AMD), highly myopia and Vogt Koyanagi-Harada disease. Similar to retinal thickness, a normal baseline choroidal thickness might be used for interpretation. This value might be affected by several variables including age, gender and ethnicity. Although there were previous studies on subfoveal choroidal thickness in normal eyes from many countries, there has been no such study in Thailand. The purpose of this study was to determine the subfoveal choroidal thickness in normal Thai eyes and study the associations with gender, age, refractive error and axial length using SD-OCT and EDI technique.
A method for generating sentences of text for selected medical findings in an electronic medical diagnostic system (10) is disclosed. First, a descriptive phrase for each medical finding is created. Each descriptive phrase is then analyzed to determine possible truncation points for modifying the descriptive phrase of one medical finding if another medical finding is also selected. A code at each possible truncation point is then entered into the phrase. Language to be inserted at each of the truncation points is then created and the descriptive phrase and modifying language are stored in database file (20) and knowledge base file (22).      Finally, the stored descriptive phrases and modifying language are then combined to form a readable text on display (12) for the medical findings selected from the databases.
It is intended to provide a hollow nanoparticle which can be easily purified and enables efficient transfer of a substance to be transferred into a cell to the target cell or tissue. Namely, a hollow nanoparticle which is made of a protein capable of forming particles and presents biological structure-recognition sites on its surface. The biological structure-recognition sites are provided at both of the N- and C-ends of the protein and recognize different chemical structures with biological origins from each other. It is preferable that at least one of them is a target structure-recognition site which recognizes a structure specific to the target cell or tissue and one of them has a function as an identification site specifically recognizing a hollow nanoparticle. As an example of the target structure-recognition site, the hepatocyte-recognition site of hepatitis B virus may be cited. As examples of the identification site, various tag sequences, etc. may be cited.
BACKGROUND: Adjuvant chemotherapy following curative surgery for locally advanced gastric cancer (AGC) significantly improves long-term patient prognosis. However, delayed chemotherapy (DC), in which patients are unable to receive timely treatment, is a common phenomenon in clinical practice for various reasons. This study aimed to investigate the impact of DC on the prognosis of patients with stage II-III locally AGC and explore the associated risk factors.
METHODS: Data from four prospective studies were included in the pooled analysis. The planned chemotherapy (PC) group was defined as the time interval between surgery and the first chemotherapy ≤ 49 d, while the DC group was defined as the time interval between surgery and chemotherapy > 49 d. The prognosis, recurrence, and risk factors were compared, and a nomogram for predicting DC was established.
RESULTS: In total, 596 patients were included, of whom 531 (89.1%) had PC and 65 (10.9%) had DC. Survival analysis revealed that the 5-year overall survival (OS) and disease-free survival (DFS) were significantly lower in the DC group than those in the PC group (log-rank P < 0.001). Cox univariable and multivariable analyses showed that DC was an independent risk factor for OS and DFS in stage II-III patients (P < 0.05). Based on the significant factors for DC, a prediction model was established that had a good fit, high accuracy (AUC = 0.780), and clinical applicability in both the training and validation sets.
CONCLUSION: Delayed chemotherapy after gastrectomy is associated with poor long-term prognosis in patients with locally advanced stage II-III GC disease. But standardized, full-cycle adjuvant chemotherapy after surgery may play a remedial role, and can to a certain extent compensate the poor effects caused by delayed chemotherapy.
The present invention relates to an oil-in-water emulsion for cosmetic use, wherein the oil particles have an average diameter ranging from 50 to 200 nm (nanometers). The nanoemulsion comprises an emulsifying system having components such as ceteareth-20, ceteareth-12, glyceryl stearate, cetearyl alcohol and cetyl palmitate. This composition imparts to the nanoemulsion an opaque coloration, besides providing to the skin inherent properties of the nanoemulsion such as better absorption of the components by the skin, imparting softness, smoothness and moisturizing for 24 hours, and may be added to products indicated for hair care. The composition of the nanoemulsion without addition of preservatives imparts a bactericidal action. The nanoemulsion is preferably used for cosmetic applications  5  for the body, face and hair in the form of milk, lotions and gels. The present invention further relates to the cosmetic compositions and cosmetic products that comprise the nanoemulsions above, as well as to a process for preparing them.
Liver fibrosis, which is caused by viral infection, toxic exposure, and autoimmune diseases, is a chronic liver disease. Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor of tissue-type plasminogen activator (tPA) and urokinase plasminogen activator, which convert plasminogen into plasmin. Therefore, PAI-1 suppresses fibrinolysis by blocking plasmin synthesis and is involved in liver fibrosis via extracellular matrix deposition. Small leucine zipper protein (sLZIP) acts as a transcription factor and plays critical roles in many cellular processes. However, the role of sLZIP in liver fibrosis remains unclear. In this study, we investigated the role of sLZIP in regulating PAI-1 transcription and liver fibrosis. sLZIP knockdown enhanced the expression of PAI-1 at the mRNA and protein levels. sLZIP knockdown also increased PAI-1 secretion and suppressed blood clot lysis by blocking tPA activity. Moreover, conditioned medium derived from sLZIP knockdown cells downregulated the expression of matrix metalloprotease (MMP)-2 and MMP-9 in the presence of tPA in hepatic stellate cells (HSCs). Liver-specific sLZIP knockout mice showed deteriorated liver fibrosis compared to control mice in a bile duct ligation-induced fibrosis model. These findings demonstrate that sLZIP functions as a negative regulator of liver fibrosis by suppressing PAI-1 transcription and HSC activation.
In hypoxic and pseudohypoxic rodent models of pulmonary hypertension (PH), hypoxia-inducible factor (HIF) inhibition attenuates disease initiation. However, HIF activation alone, due to genetic alterations or use of inhibitors of prolyl hydroxylase domain (PHD) enzymes, has not been definitively shown to cause PH in humans, indicating the involvement of other mechanisms. Given the association between endothelial cell dysfunction and PH, the effects of pseudohypoxia and its underlying pathways were investigated in primary human lung endothelial cells. PHD2 silencing or inhibition, while activating HIF2α, induced apoptosis-resistance and IFN/STAT activation in endothelial cells, independent of HIF signaling. Mechanistically, PHD2 deficiency activated AKT and ERK, inhibited JNK, and reduced AIP1 (ASK1-interacting protein 1), all independent of HIF2α. Like PHD2, AIP1 silencing affected these same kinase pathways and produced a similar dysfunctional endothelial cell phenotype, which was partially reversed by AKT inhibition. Consistent with these in vitro findings, AIP1 protein levels in lung endothelial cells were decreased in Tie2-Cre/Phd2 knockout mice compared with wild-type controls. Lung vascular endothelial cells from patients with pulmonary arterial hypertension (PAH) showed IFN/STAT activation. Lung tissue from both SU5416/hypoxia PAH rats and patients with PAH all showed AKT activation and dysregulated AIP1 expression. In conclusion, PHD2 deficiency in lung vascular endothelial cells drives an apoptosis-resistant and inflammatory phenotype, mediated by AKT activation and AIP1 loss independent of HIF signaling. Targeting these pathways, including PHD2, AKT, and AIP1, holds the potential for developing new treatments for endothelial dysfunction in PH.NEW & NOTEWORTHY HIF activation alone does not conclusively lead to human PH, suggesting that HIF-independent signaling may also contribute to hypoxia-induced PH. This study demonstrated that PHD2 silencing-induced pseudohypoxia in human lung endothelial cells suppresses apoptosis and activates STAT, effects that persist despite HIF2α inhibition or knockdown and are attributed to AKT and ERK activation, JNK inhibition, and AIP1 loss. These findings align with observations in lung endothelial cells and tissues from PAH rodent models and patients.
FIELD: chemistry. ^ SUBSTANCE: in formula I X is C-R6 or N, R1 is hydrogen, R2 is selected from a group comprising (lower)alkyl unsubstituted or substituted with one, two or three substitutes, independently selected from a group comprising hydroxy, (lower)alkoxy, fluoro(lower)alkyl, phenyl, C3-8cycloalkyl and a 6-member saturated heterocyclic ring containing two heteroatoms selected from nitrogen and oxygen atoms, C3-8cycloalkyl, unsubstituted or substituted hydroxyl, 5- or 6-member saturated heterocyclic ring containing one nitrogen atoms, where the said heterocyclic ring is unsubstituted or substituted hydroxy, fluoro(lower)alkyl, bicyclo[4.1.0]hept-7-yl, unsubstituted or condensed with a phenyl ring; and 4,7,7-trimethylbicyclo[2.2.1]hept-2-yl, substituted with one substituted independently selected from a group comprising hydroxy, (lower)alkoxy and (lower)acyloxy, R3 is a 5- or 6-member saturated heterocyclic ring containing one or two oxygen atoms, where the said heterocyclic ring is unsubstituted or substituted with one or two substitutes independently selected from a group comprising (lower)alkyl and alkoxycarbonyl, or condensed with a phenyl ring, or R2 is a pyrrolidine ring which is unsubstituted or substituted with (lower)alkyl and alkoxycarbonyl. Values of the rest of the radicals are given in the formula of invention. The invention also relates to a pharmaceutical composition containing the disclosed compound as an active ingredient. ^ EFFECT: disclosed compounds have antagonistic activity towards cannabinoid receptors CB1 and can be used as therapeutically active substance for preparing medicinal agents with antagonistic activity towards cannabinoid receptors CB1. ^ 20 cl, 74 ex
Continuous hybridoma cell lines have been produced that secrete monoclonal antibodies to the PfHRP-II antigen of blood stage P.falciparum. One of these, designated MAb 87-2B2, is of the IgM isotype. MAb 87-1D6, MAb 87-1D10, MAb 87-2G12, and MAb 87-1E1 are of isotype IgG1 or IgM. The monoclonal antibodies of the present invention are well suited for use in immunometric assays for the quantitative and qualitative detection of the PfHRP-II antigen. Also disclosed are anti-idiotypic and anti anti-idiotypic antibodies to the monoclonal antibodies of the present invention. The antibodies and antigen of the present invention are useful for immunodiagnostic and immunotherapeutic treatment of P.falciparum malaria in animals, including humans.
Patients receiving only traditional therapy. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive treatment of traditional therapy.
Transcranial galvanic stimulation (tDCS), seems to promote motor recovery after stroke by stimulating (anodal) or inhibiting (cathodal) neural circuits in the brain. In the treatment of severe lower limb paresis after stroke, the GangTrainer GT1 (GT) proved to be effective. Therefore the present study intends to combine both approaches, tDCS + GT, apply at the same time every day for two weeks in order to improve the effectiveness of GangTrainer therapy in the gait rehabilitation. The rehabilitation programme are compose 3 kinds of locomotor training interventions (experimental group, control group 1 and control group 2).

During intervention experimental group, patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital. The anodal stimulation is expected to facilitate the activity of the lower limb motor area side directly, while the cathodal stimulation of the non-lesioned hemisphere is expected to facilitate the lesioned side indirectly by decreasing inhibitory inputs. The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation, and the control group 2 receive a total of 10 treatments with convectional physiotherapy